
CLAIMS

1. Compound of formula (I):



(I)

wherein:

♦ R represents a hydrogen atom, a halogen atom or an alkyl group,

♦ Z1, Z2, Z3, independently each represents a carbon or a nitrogen atom, it being understood that the 6-membered cycle containing Z1, Z2 and Z3 can have 0, 1 or 2 nitrogen atoms,

♦ -X1- is absent or represents -O-, -S-, or -N(R'a)-, wherein R'a represents a hydrogen atom or an alkyl group,

♦ -X2- represents an alkanediyl group optionally substituted with one or more substituents, identical or different, selected from halogen atoms, polyhalogenoalkyl group, alkoxy group, hydroxy group, amino group, alkylamino group, dialkylamino group and cyano group,

it being understood that the carbon atom in the alpha position of -N(Ra), and the carbon atom in alpha position of -X1- when -X1- represents -O-, -S-, or -N(R'a)-, cannot be substituted with an oxygen or a nitrogen heteroatom,

♦ -X3- represents an alkanediyl group optionally substituted with one or more substituents, identical or different, selected from halogen atoms, polyhalogenoalkyl group, alkoxy group, hydroxy group, amino group, alkylamino group, dialkylamino group, cyano group, cycloalkyl group and heterocycloalkyl group,

it being understood that the carbon atom in alpha position of -O-, and the carbon atom in alpha position of A1 when A1 represents a nitrogen atom, cannot be substituted with


an oxygen or a nitrogen heteroatom,

♦ Ra represents a hydrogen atom or an alkyl group,

it being understood that when Ra represents an alkyl group, one carbon atom of Ra can be linked to a carbon atom of -X2-, or to a carbon atom of -X3- to form a cyclic moiety containing 5 or 6 ring-members,

♦ A represents

- an aromatic or partially hydrogenated cyclic group of the formula (a):



(a)


wherein

✓ A1, A4 each independently represents a carbon atom or a nitrogen atom,

✓ A2, A3, A5 each independently represents a carbon atom, an oxygen atom, a sulfur atom or a nitrogen atom,

it being understood that A1, A2, A3, A4 and A5 cannot simultaneously represent a heteroatom,

- or an aromatic or partially hydrogenated cyclic group of the formula (b):



(b)

wherein A'1, A'2, A'3, A'4 each independently represents a carbon atom or a nitrogen atom,

it being understood that * means that the bond is linked to X3,

the aromatic or partially hydrogenated cyclic group A such defined being optionally substituted with one or more substituents, identical or different, selected from halogen atoms, alkyl group, alkoxy group, hydroxy group, oxo group, alkoxyalkyl group, alkoxyalkoxy group, polyhalogenoalkyl group, polyhalogenoalkoxy group, heterocycloalkyl group, heterocycloalkylalkyl group, (alkoxyalkyl)(alkyl)amino group, amino group, alkylamino group, dialkylamino group, cycloalkyl group,

(heterocycloalkyl)(alkyl)amino group, dialkylaminoalkyl group, heterocycloalkylalkoxy group, cyano group and cyanoalkyl group,

wherein the heterocycloalkyl and cycloalkyl group such defined can be optionally substituted by one or more substituents chosen from alkyl group, halogen atoms, polyhalogenoalkyl group, polyhalogenoalkoxy group, alkoxy group, alkoxyalkyl group, hydroxy group, cyano group and oxo group,

their enantiomers, diastereoisomers, tautomers, racemic, hydrates, solvates, N-oxide, isotopes, deuterated derivatives and addition salts thereof with a pharmaceutically acceptable acid or base.

2. Compound according to claim 1, wherein R represents a hydrogen atom.

3. Compound according to claim 1, wherein R represents a halogen atom.

4. Compound according to any of claims 1 to 3, wherein Z1, Z2 and Z3 represent simultaneously a carbon atom.

5. Compound according to any of claim 1 to 3, wherein one of Z1 or Z2 represents a nitrogen atom and Z3 represents a carbon atom.

6. Compound according to any of claims 1 to 5, wherein -X1- represents -O-.

7. Compound according to any of claims 1 to 6, wherein -X2- represents an alkanediyl group linear or branched having 2, 3, 4 or 5 carbon atoms.


8. Compound according to claim 7, wherein -X2- represents $-(CH_2)_3-$, $-CH(CH_3)-(CH_2)_2-$, $-CH_2-CHF-CH_2-$, $-CH_2-CF_2-CH_2-$, or $-(CH_2)_2-CH(CH_3)-$.

9. Compound according to any of claims 1 to 8, wherein Ra is a hydrogen atom.

10. Compound according to any of claims 1 to 9, wherein -X3- represents an alkanediyl group linear or branched having 1, 2, 3, 4 or 5 carbon atoms.

11. Compound according to claim 10, wherein -X3- represents $-(CH_2)_2-$, $-CH_2-$ or $-CH(CH_3)-$.


12. Compound according to any of claims 1 to 11, wherein A represents a group of formula (b):



(b)

wherein A'1, A'2, A'3, A'4 and * are as defined in claim 1.

13. Compound according to claim 12, wherein A represents




such defined A groups being not substituted or optionally substituted.

14. Compound according to claim 12 wherein A represents a phenyl group.

15. Compound according to claim 12 wherein A represents a pyridinyl group.

16. Compound according to claim 12 wherein A represents a pyrazinyl group.


17. Compound according to claims 1 to 11, wherein A represents a group of formula (a):



(a)

wherein A1, A2, A3, A4, A5 and * are as defined in claim 1.

18. Compound according to claim 17, wherein A represents



such defined A groups being not substituted or optionally substituted.


19. Compound according to claim 17 wherein A represents a triazolyl group.

20. Compound according to claim 17 wherein A represents a pyrazolyl group.

21. Compound according to claims 12 to 20, wherein A is not substituted.

22. Compound according to claims 12 to 20, wherein A is substituted with one or more groups chosen from halogen atoms, cyano group, cyanoalkyl group, oxo group, alkoxy group, alkyl group, cycloalkyl group and heterocycloalkyl group.


23. Compound according to claim 1, which is compound of formula (I-a):



(I-a)

wherein X1, X2, X3, Ra and A are as defined in claim 1.


24. Compound according to claim 23, which is compound of formula (I-b):




(I-b)

wherein X2, X3, Ra and A are as defined in claim 1.

25. Compound according to claim 23, which is compound of formula (I-c) or (I-c'):




(I-c)




(I-c')

wherein X1, X2, X3, Ra, A'1, A'2 and A'4 are as defined in claim 1.

26. Compound according to claim 23 or 25, which is compound of formula (I-d) or (I-d'):




(I-d)



(I-d')

wherein X2, X3, Ra, A'1, A'2 and A'4 are as defined for formula (I).


27. Compound according to claim 23, which is compound of formula (I-e):



(I-e)

wherein X1, X2, X3, Ra, A1, A2 and A5 are as defined for formula (I).

28. Compound according to claim 23 or 27, which is compound of formula (I-f):



(I-f)

wherein X2, X3, Ra, A1, A2 and A5 are as defined for formula (I).

29. Compound according to claim 23, 25 or 27, wherein the -X1-X2-N(Ra)-C(O)O-X3- chain represents -O-$(CH_2)_3$-NHC(O)O-CH_2-, -O-CH(CH_3)-$(CH_2)_2$-NHC(O)O-CH_2-, -O-CH_2-CHF-CH_2-NHC(O)O-CH_2-, -O-CH_2-CF_2-CH_2-NHC(O)O-CH_2-, -O-CH(CH_3)-$(CH_2)_2$-NHC(O)O-$(CH_2)_2$- or -O-CH(CH_3)-$(CH_2)_2$-NH-C(O)O-CH(CH_3)-.

30. Compounds according to claim 1 which are:

- 8,14-dioxa-4,10,19,20-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 10-methyl-8,14-dioxa-4,10,19,20-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4, 6(23),15,17,21-heptaen-9-one;
- 4-fluoro-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;
- 8,14-dioxa-10,19,20,23-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;
- 8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 10-(propan-2-yl)-8,14-dioxa-4,10,19,20-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 8,14-dioxa-5,10,19,20-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;

- 4-methoxy-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-bromo-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;
- 5-fluoro-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;

- 5-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;
- 4-(pyrrolidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2,4,6(23),15,17,21-heptaen-9-one;
- 4-[4-(propan-2-yl)piperazin-1-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-{2-oxa-6-azaspiro[3.4]octan-6-yl}-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[4-(oxetan-3-yl)piperazin-1-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-(morpholin-4-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2,4,6(23),15,17,21-heptaen-9-one;
- 4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;
- 5-methoxy-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15, 17,21-heptaen-9-one;
- 4-(4,4-difluoropiperidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 4-(3,3-difluoropyrrolidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 7-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[4-(2-methoxyethyl)piperidin-1-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa -1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 9,14-dioxa-11,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-10-one;
- 4-[(3R)-3-hydroxypyrrolidin-1-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[(2-methoxyethyl)(methyl)amino]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-chloro-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;
- 4-fluoro-5-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2, 4,6(23),15,17,21-heptaen-9-one;
- 4,5-difluoro-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4, 6(23),15,17,21-heptaen-9-one;
- 5-bromo-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 4-(4-methylpiperazin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-(3-methoxyazetidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2, 4,6(23),15,17,21-heptaen-9-one;
- 1-{9-oxo-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-4-yl}piperidine-4-carbonitrile;
- 4-[4-(pyrrolidin-1-yl)piperidin-1-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-(azetidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2, 4,6(23),15,17,21-heptaen-9-one;
- 4-(piperidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2, 4,6(23),15,17,21-heptaen-9-one;
- 4-(2,5-dihydrofuran-3-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[4-(morpholin-4-yl)piperidin-1-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 4-[(2S,5S)-2,5-dimethylmorpholin-4-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 4-[(morpholin-4-yl)methyl]-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[(pyrrolidin-1-yl)methyl]-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[(pyrrolidin-1-yl)methyl]-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[(4-methylpiperazin-1-yl)methyl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 5-(morpholin-4-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[4-(2-methoxyethyl)piperazin-1-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-(diethylamino)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2, 4,6(23),15,17,21-heptaen-9-one;
- 4-cyclopropyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2, 4,6(23),15,17,21-heptaen-9-one;
- 5-(4-methylpiperazin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;

- 8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20),2(23),3, 15(22),16,18(21)-hexaen-9-one;
- 4-[methyl(oxetan-3-yl)amino]-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2. 1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[(dimethylamino)methyl]-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4,10-dimethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4, 6(23),15,17,21-heptaen-9-one;
- 4-(propan-2-yloxy)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 4-fluoro-7-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-(3-methylpiperidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-[(3S)-3-hydroxypyrrolidin-1-yl]-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-fluoro-8,14-dioxa-10,19,20-triazapentacyclo[13.5.2.1^{2,6}.1^{7,10}.0^{18,21}]tetracosa-1(20), 2(24),3,5,15(22),16,18(21)-heptaen-9-one;

- 4-(oxolan-3-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2,4,6(23),15,17,21-heptaen-9-one;
- (13S)-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 4-(1-methyl-1H-pyrazol-3-yl)-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (7S)-7-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 4-[2-(morpholin-4-yl)ethoxy]-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2. 1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 4-(2-methoxyethyl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2(23), 3,5,15(22),16,18(21)-heptaen-9-one;
- (7R)-7-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 5-cyclopropyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 4-(2-methoxyethoxy)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 4-fluoro-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2,4,6(23),15,17,21- heptaen-9-one;

- 11-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;
- 4-(3-oxomorpholin-4-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 4-(2-oxopyrrolidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 5-(2-oxopyrrolidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 4-(2-methylpyrrolidin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 2-{9-oxo-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23), 3,5,15(22),16,18(21)-heptaen-4-yl}acetonitrile;
- (11R)-11-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (11S)-11-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 4-ethynyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;

- 4-(piperazin-1-yl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20), 2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 4-(1,2,3,6-tetrahydropyridin-4-yl)-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 11-(methoxymethyl)-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 8,14-dioxa-5,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20),2(23),3, 15(22),16,18(21)-hexaen-9-one;
- 11-methyl-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20), 2(23),3,15(22),16,18(21)-hexaen-9-one;
- 12-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5, 15(22),16,18(21)-heptaen-9-one;
- 11-ethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5, 15(22),16,18(21)-heptaen-9-one;

- 4-fluoro-5,7-dimethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2(23), 3,5,15(22),16,18(21)-heptaen-9-one;
- 4-fluoro-5-methoxy-7-methyl-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 5-fluoro-4,7-dimethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;

- 8,14-dioxa-10,19,20-triazapentacyclo[13.5.2.$1^{2,6}$.$1^{7,10}$.$0^{18,21}$]tetracosa-1(20),2(24),3,5, 15(22),16,18(21)-heptaen-9-one;
- 13-methyl-8,14-dioxa-10,19,20,23-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20), 2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 12-methyl-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.$1^{2,5}$.$0^{18,21}$]tricosa-1(20), 2(23),3,15(22),16,18(21)-hexaen-9-one;
- 7-methyl-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.$1^{2,5}$.$0^{18,21}$]tricosa-1(20), 2(23),3,15(22),16,18(21)-hexaen-9-one;
- 5-fluoro-4-methoxy-7-methyl-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (7R,13R)-7,13-dimethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.$1^{2,5}$.$0^{18,21}$] tricosa-1(20),2(23),3,15,17,21-hexaen-9-one;
- 8,15-dioxa-4,10,20,21-tetraazapentacyclo[14.5.2.$1^{2,6}$.$1^{10,13}$.$0^{19,22}$]pentacosa-1(21),2(25), 3,5,16(23),17,19(22)-heptaen-9-one;
- 8,14-dioxa-5,10,19,20-tetraazatetracyclo[13.5.2.$1^{2,5}$.$0^{18,21}$]tricosa-1(20),2(23),3,15(22),16,18(21)-hexaen-9-one;
- (13S)-4-fluoro-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;

- (13R)-4-fluoro-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-4,10,19,20-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 6-cyclopropyl-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.$1^{2,5}$.$0^{18,21}$]tricosa-1(20), 2(23),3,15(22),16,18(21)-hexaen-9-one;

- 7-ethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (13R)-13-ethyl-8,14-dioxa-5,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23), 15,17,21-heptaen-9-one;
- (7R,13R)-4-fluoro-7,13-dimethyl-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 7-methyl-8,14-dioxa-4,10,19,20-tetraazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4, 6(23),15,17,21-heptaen-9-one;
- (7R)-4-fluoro-7-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (7S)-4-fluoro-7-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 6-methyl-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20), 2(23),3,15,17,21-hexaen-9-one;

- 7-methyl-8,14-dioxa-10,19,20,23-tetraazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4, 6(23),15,17,21-heptaen-9-one;
- 6-(propan-2-yl)-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20),2(23),3,15(22),16,18(21)-hexaen-9-one;
- (13R)-7,13-dimethyl-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20),2(23),3,15(22),16,18(21)-hexaen-9-one;
- (13R)-13-methyl-8,14-dioxa-10,19,20,23-tetraazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (7R)-7-ethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4, 6(23),15, 17,21-heptaen-9-one;
- (7S)-7-ethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4, 6(23),15,17,21-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-5,10,19,20-tetraazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 6-(oxan-4-yl)-8,14-dioxa-4,5,10,19,20-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20),2(23),3,15,17,21-hexaen-9-one;
- 4-ethyl-8,14-dioxa-5,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20), 2(23),15,17,21-pentaen-9-one;

- (13R)-23-fluoro-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 9,14-dioxa-4,5,11,19,20-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20),2(23), 3,15,17,21-hexaen-10-one;
- 4-ethyl-8,14-dioxa-5,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20), 2(23),3,15,17,21-hexaen-9-one;
- 3,9,15-trioxa-4,11,20,21-tetraazatetracyclo[14.5.2.1^{2,5}.0^{19,22}]tetracosa-1(21),2(24), 4,16,18,22-hexaen-10-one;
- (13R)-16-fluoro-13-methyl-8,14-dioxa-4,10,19,20-tetraazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (13R)-4-chloro-13-methyl-8,14-dioxa-10,19,20,23-tetraazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 8,14-dioxa-2,4,10,19,20-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20),3,5(23), 15(22),16,18(21)-hexaen-9-one;
- (13R)-4-methoxy-13-methyl-8,14-dioxa-10,19,20,23-tetraazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (13R)-13-methyl-9-oxo-8,14-dioxa-10,19,20-triazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaene-5-carbonitrile;
- (13R)-13-methyl-4-(pyrrolidin-1-yl)-8,14-dioxa-5,10,19,20,23-pentaazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (7S,13R)-7,13-dimethyl-8,14-dioxa-5,10,19,20,23-pentaazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- (7R,13R)-7,13-dimethyl-8,14-dioxa-5,10,19,20,23-pentaazatetracyclo[13.5.2. 1^{2,6}.0^{18,21}]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (13R)-16-fluoro-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-4,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 8,14-dioxa-4-thia-10,19,20,23-tetraazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20),2,5(23), 15,17,21-hexaen-9-one;
- 8,14-dioxa-3-thia-10,19,20,23-tetraazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20),2(23),4,15,17,21-hexaen-9-one;

- (7R,13R)-7,13-dimethyl-8,14-dioxa-10,19,20,23-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (13R)-4-[(3R)-3-methoxypyrrolidin-1-yl]-13-methyl-8,14-dioxa-5,10,19,20,23-pentaazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (13R)-16-chloro-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2, 4,6(23),15,17,21-heptaen-9-one;
- (13R)-13,16-dimethyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2,4, 6(23),15,17,21-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-3,10,19,20,23-pentaazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;

- 8-oxa-10,14,19,20-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2(23),3,5, 15(22),16,18(21)-heptaen-9-one hydrochloride;
- 8-oxa-10,19,20-triazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2(23),3,5,15(22),16, 18(21)-heptaen-9-one;
- (13R)-5-methoxy-13-methyl-8,14-dioxa-4,10,19,20-tetraazatetracyclo [13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-4,10,19,20-tetraazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2, 6(23),15,17,21-hexaene-5,9-dione;
- 4-methyl-8,14-dioxa-3,4,10,19,20-pentaazatetracyclo[13.5.2.$1^{2,5}$.$0^{18,21}$]tricosa-1(20),2, 5(23),15(22),16,18(21)-hexaen-9-one;
- (13R)-16-fluoro-13-methyl-8,14-dioxa-10,19,20,23-tetraazatetracyclo [13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2,4,6(23),15,17,21-heptaen-9-one;
- 7,13-dioxa-4-thia-9,18,19,22-tetraazatetracyclo[12.5.2.$1^{2,5}$.$0^{17,20}$]docosa-1(19),2,5(22),14(21),15,17(20)-hexaen-8-one;
- (13R)-4,13-dimethyl-8,14-dioxa-5,10,19,20,23-pentaazatetracyclo[13.5.2.$1^{2,6}$.$0^{18,21}$] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 8,14-dioxa-23-thia-4,10,19,20-tetraazatetracyclo[13.5.2.$1^{2,5}$.$0^{18,21}$]tricosa-1(20),2,4,15(22), 16,18(21)-hexaen-9-one;
- (7S,13R)-7,13-dimethyl-8,14-dioxa-10,19,20,23-tetraazatetracyclo [13.5.2.$1^{2,6}$.$0^{18,21}$]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;

- (13R)-13-methyl-9-oxo-8,14-dioxa-5,10,19,20-tetraazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20), 2(23),3,15(22),16,18(21)-hexaene-4-carbonitrile;
- 12,12-difluoro-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23), 3,5,15(22),16,18(21)-heptaen-9-one;
- (13R)-17-fluoro-13-methyl-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (7S,13R)-7,13-dimethyl-8,14-dioxa-4,10,19,20,23-pentaazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (7R,13R)-7,13-dimethyl-8,14-dioxa-4,10,19,20,23-pentaazatetracyclo [13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (13S)-13-methyl-8,14-dioxa-4,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-10,19,20,22-tetraazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20), 2(23),3,5,15,17,21-heptaen-9-one ;
- (12R)-4,12-dimethyl-7,13-dioxa-4,9,18,19,22-pentaazatetracyclo[12.5.2.1^{2,5}.0^{17,20}] docosa-1(19),2,5(22),14(21),15,17(20)-hexaen-8-one;
- (13R)-13-methyl-8,14-dioxa-4,5,10,19,20,23-hexaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20),2(23),3,15,17,21-hexaen-9-one;
- (13R)-13-methyl-8,14-dioxa-23-thia-4,10,19,20-tetraazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20),2,4,15,17,21-hexaen-9-one ;

- (13R)-4,13-dimethyl-8,14-dioxa-4,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20),2,5(23),15(22),16,18(21)-hexaen-9-one;
- (13R)-13-methyl-8,14-dioxa-10,16,19,20-tetraazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;
- 14-methyl-8-oxa-10,14,19,20-tetraazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23),3,5, 15,17,21-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-4,10,19,20,22-pentaazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15,17,21-heptaen-9-one;
- (13R)-13-methyl-8,14-dioxa-10,17,19,20-tetraazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;

- 8,14-dioxa-4,5,10,19,20,23-hexaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}]tricosa-1(20),2(23),3, 15(22),16,18(21)-hexaen-9-one;
- 12,12-difluoro-8,14-dioxa-4,5,10,19,20,23-hexaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20),2(23),3,15(22),16,18(21)-hexaen-9-one;
- (12R)-12-fluoro-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23), 3,5,15(22),16,18(21)-heptaen-9-one;
- (12S)-12-fluoro-8,14-dioxa-10,19,20-triazatetracyclo[13.5.2.1^{2,6}.0^{18,21}]tricosa-1(20),2(23), 3,5,15(22),16,18(21)-heptaen-9-one;
- 12,12-difluoro-8,14-dioxa-4,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15(22),16,18(21)-heptaen-9-one;

- (12S)-12-fluoro-8,14-dioxa-4,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15,17,21-heptaen-9-one;
- (12R)-12-fluoro-8,14-dioxa-4,10,19,20,23-pentaazatetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosa-1(20),2(23),3,5,15,17,21-heptaen-9-one;
- (12S)-12-fluoro-8,14-dioxa-4,5,10,19,20,23-hexaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20),2(23),3,15,17,21-hexaen-9-one;
- (12R)-12-fluoro-8,14-dioxa-4,5,10,19,20,23-hexaazatetracyclo[13.5.2.1^{2,5}.0^{18,21}] tricosa-1(20),2(23),3,15,17,21-hexaen-9-one;
- 8',14'-dioxa-10',19',20'-triazaspiro[cyclopropane-1,13'-tetracyclo[13.5.2.1^{2,6}.0^{18,21}] tricosane]-1'(20'),2'(23'),3',5',15'(22'),16',18'(21')-heptaen-9'-one.

31. Pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 30 or an addition salt thereof with a pharmaceutically acceptable acid or base in combination with one or more pharmaceutically acceptable excipients.

32. Pharmaceutical composition according to claim 31 for use as inhibitor of LRRK2 kinase activity.

33. Pharmaceutical composition according to claim 31 for use in the treatment of neurological diseases, endosomal-lysosomal disorders, inflammatory diseases, bacterial, viral and parasitic infections, cardiovascular diseases, autoimmune diseases and cancers.

34. Pharmaceutical composition for use according to claim 33 wherein the neurological disease is selected from Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dementia, diabetic neuropathy, age related memory disfunction, mild cognitive impairment, argyrophilic grain disease, Pick's disease, epilepsy, tauopathies such as progressive supranuclear palsy and corticobasal degeneration, other synucleinopathies such as multiple system atrophy, frontotemporal dementia, inherited frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), withdrawal symptoms/relapse associated with drug addiction, L-Dopa induced dyskinesia, ischemic stroke, traumatic brain injury, spinal cord injury and multiple sclerosis.

35. Pharmaceutical composition for use according to claim 34 for use in the treatment of Parkinson's disease or Alzheimer's disease.

36. Pharmaceutical composition for use according to claim 33 wherein the endosomal-lysosomal disorder is selected from Niemann-Pick Type A, B or C disease, Gaucher's disease, Krabbe's disease, Fabry's disease and disorders with mitochondrial deficits.

37. Pharmaceutical composition for use according to claim 33 wherein the inflammatory disease is selected from vasculitis, pulmonary diseases such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, inflammatory myopathies, ankylosing spondylitis.

38. Pharmaceutical composition for use according to claim 33 wherein autoimmune disease is selected from Crohn's disease, inflammatory bowel disease, rheumatoid arthritis, ulcerative colitis, lupus, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, type I diabetes mellitus, obesity, Evans syndrome, bullous skin disorders, Sjogren's syndrome, Devic's disease and leprosy.

39. Pharmaceutical composition for use according to claim 33 wherein cancer is selected from thyroid cancer, renal cancer, breast cancer, hormone-related cancer, adeno-and squamous lung cancer, non-small-cell lung cancer, colon cancer, prostate cancers, skin cancers, leukemias and lymphomas.

40. Pharmaceutical composition for use according to claim 33 wherein cardiovascular disease is stroke.

41. Pharmaceutical composition for use according to claim 33 wherein bacterial or viral infections are selected from leprosy, tuberculosis, SARS-CoV, MERS-CoV and SARS-CoV-2, HIV, West Nile virus and chikungunya virus.

42. Compound of formula (I) according to any one of claims 1 to 30, or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dementia, diabetic neuropathy, age related memory disfunction, mild cognitive impairment, argyrophilic grain disease, Pick's disease, epilepsy, tauopathies such as progressive supranuclear palsy and corticobasal degeneration, other synucleinopathies, frontotemporal dementia, inherited frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), withdrawal symptoms/ relapse associated with drug addiction, L-Dopa induced dyskinesia, ischemic stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, Niemann-Pick Type A, B or C disease, Gaucher's disease, Krabbe's disease, Fabry's disease, disorders with mitochondrial deficits, Crohn's disease, inflammatory bowel disease, rheumatoid arthritis, ulcerative colitis, lupus, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, type I diabetes mellitus, obesity, Evans syndrome, bullous skin disorders, Sjogren's syndrome, Devic's disease, leprosy, thyroid cancer, renal cancer (including papillary renal), breast cancer, hormone-related cancer, adeno-and squamous lung cancer, non-small-cell lung cancer, colon cancer, prostate cancers, skin cancers, leukemias (including acute myelogenous leukemia), lymphomas, stroke, leprosy, tuberculosis, and SARS-CoV, MERS-CoV, SARS-CoV-2, HIV, West Nile virus and chikungunya virus infections.